A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Crizotinib (Primary) ; Erlotinib (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 02 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2021.